Lunit Presents 5 Research Results on 'Lunit Scope' at ESMO

Lunit Scope IO and Lunit Scope PD-L1

[Asia Economy Reporter Chunhee Lee] Lunit announced on the 5th that it will present five poster studies applying artificial intelligence (AI) biomarkers to various cancer types, including breast cancer and urothelial carcinoma, at the 2022 European Society for Medical Oncology (ESMO 2022) held in Paris, France, from the 9th to the 13th.

ESMO is the largest cancer academic conference in Europe, with more than 25,000 members from 160 countries worldwide, including cancer specialists and global pharmaceutical and bio experts. It is considered one of the world's top three cancer societies alongside the American Society of Clinical Oncology (ASCO) and the American Association for Cancer Research (AACR).

At this ESMO, Lunit will present research results using its AI biomarker platform and AI pathology analysis solution, 'Lunit SCOPE,' including ▲prediction of breast cancer treatment efficacy ▲measurement of tumor purity ▲validation of AI performance for urothelial carcinoma PD-L1 ▲quantitative analysis of tumor-infiltrating lymphocytes (TIL) in neuroendocrine neoplasm ▲discovery of new targets for antibody-drug conjugates (ADC).

The first study on predicting breast cancer treatment efficacy was led by Professors Sangyong Song, Eun-yoon Jo, and Su-yeon Cho from the Department of Pathology at Samsung Medical Center. Applying Lunit SCOPE to HER2-positive early breast cancer patients, the HER2 expression interpretation results were found to be at the level of pathology specialists. Professor Sangyong Song, who led the research, explained, “Using Lunit SCOPE HER2 to analyze the important breast cancer biomarker HER2 expression in patients undergoing breast cancer treatment showed a high concordance with the results interpreted by pathology specialists using traditional methods. Additionally, through cell-level and tumor-infiltrating lymphocyte evaluations, we confirmed that Lunit SCOPE can play an auxiliary role in predicting the efficacy of neoadjuvant chemotherapy.”

The second poster presentation will reveal results measuring tumor purity using Lunit SCOPE. Tumor purity indicates the proportion of cancer cells within cancer tissue. The more accurate the measurement, the better it serves as a means to propose personalized treatment methods for cancer patients. The study will present that tumor purity predicted based on hematoxylin and eosin (H&E) pathology images using Lunit SCOPE shows a high correlation with results actually analyzed by next-generation sequencing (NGS).

The third poster presents results evaluating the combined positive score (CPS) of the biomarker PD-L1 using Lunit SCOPE in 543 urothelial carcinoma patients in Korea. Generally, a CPS of 10 or higher is known to indicate a high response to immunotherapy. Lunit SCOPE evaluated PD-L1 CPS at a level similar to pathology specialists.

The fourth study quantitatively analyzed the expression of immune cells, TIL, in neuroendocrine neoplasms using Lunit SCOPE. It will be announced that AI biomarkers can serve as a means to predict immunotherapy response in neuroendocrine neoplasms, where standardized biomarkers are lacking.

The final poster will present research results on discovering new targets with specific overexpression and DNA amplification on tumor cell membranes using Lunit SCOPE and the potential for developing these as new treatments such as ADCs.

Seobum Seok, CEO of Lunit, said, "Lunit SCOPE’s technology is being recognized through numerous global conferences, including this ESMO. Especially at this ESMO, as we present many research results expanded to various cancer types, we expect the utilization value of Lunit SCOPE to grow even further.”

This content was produced with the assistance of AI translation services.